RSS Facebook Twitter YouTube

Transplantation

Single dose of ZA pre-transplant prevents bone loss

Erilyn Riley Read Article
Published: 03/02/17

Bone_density_scanner_Steven_Fruitsmaak.jpg
Bone density scanner
Photo by Steven Fruitsmaak

A single, 4 mg-dose of the bisphosphonate zoledronic acid (ZA) prior to allogeneic hematopoietic stem cell transplant (HSCT) prevents femoral neck (FN) bone loss at day 100 in patients with lymphoid or myeloid malignancies, according to new research. And patients who receive risk-adapted ZA therapy after transplant can significantly reduce bone loss between days 100 and 365. However, patients with acute and chronic graft-versus-host disease (GVHD) continue to be at risk of bone loss. [Read Article]

VZV vaccine reduces HZ incidence after HSCT

HT Staff Read Article
Published: 02/28/17

vaccine-nci-bill-branson-230.jpg
Doctor vaccinating a patient
Photo by Bill Branson

Results of a phase 3 trial suggest an inactivated varicella zoster virus (VZV) vaccine known as V212 can reduce the risk of herpes zoster (HZ) in patients who have undergone autologous hematopoietic stem cell transplant (HSCT). V212 reduced the hazard rate of HZ by an estimated 64% compared to placebo. The vaccine also reduced the incidence of moderate-to-severe HZ pain and other HZ-related complications, such as hospitalization. [Read Article]

Inpatient palliative care improves QOL for HSCT patients

Erilyn Riley Read Article
Published: 02/27/17

doctor_and_hospitalized_patient_smiling_Credit_CDC_230.jpg
Doctor and hospitalized patient
Photo courtesy of CDC

New research shows that patients who received inpatient palliative care while undergoing hematopoietic stem cell transplant (HSCT) experienced significant improvements in quality of life (QOL), decreases in depression, and reductions in symptom burden compared to patients who received transplant care alone. Areej R. El-Jawahri, MD, of Harvard Medical School in Boston, Massachusetts, presented these results at the 2017 BMT Tandem Meetings. [Read Article]

FDA expands approved indication for lenalidomide

HT Staff Read Article
Published: 02/23/17

lenalidomide_revlimid_bottle_celgene_230.jpg
Lenalidomide (Revlimid)
Photo courtesy of Celgene

The US Food and Drug Administration (FDA) has approved a new indication for lenalidomide (Revlimid). The drug is now approved for use as maintenance therapy after autologous hematopoietic stem cell transplant (auto-HSCT) in patients with multiple myeloma (MM). The expanded indication makes lenalidomide the first treatment to receive FDA approval for maintenance following auto-HSCT. [Read Article]

Immunotherapy receives fast track designation

HT Staff Read Article
Published: 02/22/17

ebv-cell-190.jpg
EBV-infected cell (green/red)
among uninfected cells (blue)
Image courtesy of
Benjamin Chaigne-Delalande

The US Food and Drug Administration (FDA) has granted fast track designation to CMD-003 (baltaleucel-T) for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with Epstein-Barr virus (EBV). CMD-003 consists of patient-derived T cells that have been activated to kill malignant cells expressing antigens associated with EBV. The T cells specifically target 4 EBV epitopes—LMP1, LMP2, EBNA, and BARF1. [Read Article]

 

{title}

{icon} {author} Read Article
Published: {pubDate}

{summary}